Investigational New Drugs

, Volume 1, Issue 3, pp 219–224 | Cite as

Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG)

  • Milan Slavik
  • Thomas Clouse
  • Alan Wood
  • Oscar Blanc
  • Robert C. Eschbach


Using a paired ion exchange high pressure liquid Chromatographic assay, pharmacokinetic evaluation of methyl glyoxal bis guanylhydrazone (methyl-GAG) was performed in nine male New Zealand albino rabbits following administration of a single intravenous bolus dose of 50 mg/kg B.W (550 mg/m2 BSA).

Blood samples were collected before and at intervals of 5, 10, 15, 30 min and 1, 2, 3, 4, 6, 8, 12, 18, and 24 h after administration of the drug.

The analysis of experimental data indicates a three compartment open model with first order elimination from the central compartment described by the equation C pt =A.e−αt+B.e−βt+C.e−γt, where A, B, C, are 107.985, 4.785, and 0.763 μg/ml, respectively, α, β,γ, are 5.466, 0.487, and 0.030 h−1, respectively, and \(T_{\frac{1}{2}\alpha ,\beta ,\gamma } \) are 7.6, 85.3 min and 23.1 h, respectively. The mean volume of distribution in the central compartment V c was 0.44 liters (l)/kg, volume of distribution Vd area 30.326 l/kg, and the total body clearance 0.9097 l/kg/h. The existence of a long terminal plasma half life of methyl-GAG reported previously in human studies was also confirmed in experimental animals and may explain the cumulative toxicity of this drug.

Key words

methyl-GAG rabbits pharmacokinetics three compartmental model 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Freedlander BL, French FA: Carcinostatic action of polycarbonyl compounds and their derivatives II: Glyoxal-bis-(guanylhydrazone) and derivatives. Cancer 18:360–363, 1958Google Scholar
  2. 2.
    Thiele J, Dralle E: Zur Kenntnis des Amidoguanidins I. Condensationsproducte des Aminoguanidins mit Aldehyden und Ketonen der Fettreihe. Annalen Der Chemie (Liebig) 302:275–299, 1898Google Scholar
  3. 3.
    Regelson W, Holland JF: Clinical study of parenteral methyl glyoxal bis (guanylhydrazone) diacetate. Cancer Chemother Rep 11:81–86, 1961Google Scholar
  4. 4.
    Freireich EJ, Frei E III, Karon M: Methyl glyoxal bis (guanyl-hydrazone): A new agent active against acute myelocytic leukemia. Cancer Chemother Rep 16:183–186, 1962Google Scholar
  5. 5.
    Levin R, Henderson E, Karon M, Freireich EJ: Treatment of acute leukemia with methyl-glyoxal-bis guanylhydrazone (Methyl-GAG). Clin Pharmacol Ther 6:31–42, 1965Google Scholar
  6. 6.
    Knight WA, Livingston RB, Fabian C, Constanzi J: Phase I –II trial of methyl-GAG: A Southwest Oncology Group pilot study. Cancer Treat Rep 63:1933–1937, 1979Google Scholar
  7. 7.
    Oliverio VT, Adamson RH, Henderson ES, Davidson JD: The distribution excretion and metabolism of methyl glyoxal-bis-guanylhydrazone-C14. J Pharm Exp Ther 141: 149–156, 1963Google Scholar
  8. 8.
    Killen J, Hoth D, Smith F, Schein P, Woolley P: Methylglyoxal-bis-guanylhydrazone (NSC 32946) Methyl-G: Phase II experience and clinical pharmacology. Proc ACCR, ASCO 21:3681, 1980Google Scholar
  9. 9.
    Liesmann J, Fabian C, Stephens R, Marsh K: Pharmacokinetics of methyl-gloxyl-bis-guanylhydrazone (MGBG). Proc AACR, ASCO 21:151, 1980Google Scholar
  10. 10.
    Marsh KC, Liesmann J, Patton TF, Fabian CJ, Sternson LA: Plasma levels and urinary excretion of methyl-GAG following IV infusion in man. Cancer Treat Rep 65:253–257, 1981Google Scholar
  11. 11.
    Hart RD, Roboz J, Wu K, Bruckner H, Ohnuma T, Holland JF: Clinical and pharmacologic studies with weekly and biweekly methyl-glyoxal-bis-guanylhydrazone (Methyl-G). Proc ASCO, AACR 21:181, 1980Google Scholar
  12. 12.
    Rosenblum MG, Keating MJ, Yap BS, Loo TL: Pharmacokinetics of (14C) Methyl glyoxal-bis (Guanylhydrazone) in patients with leukemia. Cancer Res 41:1748–1750, 1981Google Scholar
  13. 13.
    Marsh KC, Repta AJ, Sternson LA: A high performance liquid chromatographic assay for methyl glyoxal bis (guanylhydrazone) Methyl-GAG in plasma and urine. J Chromatography 187:101–109, 1980Google Scholar
  14. 14.
    Wagner J: Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. Pharmacokin Biopharm 4(5):443–467, 1976Google Scholar
  15. 15.
    Slavik M, Mayfield A, Wood A, Blanc O: Pharmacokinetic studies with α difluoromethylornithine (αDFMO). Proc AACR 23:203, 1982Google Scholar
  16. 16.
    Bachur NR, Hildebrand RC, Jaenke RS: Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther 191:331–340, 1974Google Scholar
  17. 17.
    Ames MM, Kovach JS: Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Cancer Treat Rep 66:1579–1581, 1982Google Scholar
  18. 18.
    Slavik M, Carter SK: Chromomycin A3 mithramycin and olivomycin: Antitumor antibiotics of related structure. Adv Pharmacol Chemother 12:1–30, 1975Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • Milan Slavik
    • 1
    • 2
    • 3
  • Thomas Clouse
    • 1
  • Alan Wood
    • 1
  • Oscar Blanc
    • 1
  • Robert C. Eschbach
    • 4
  1. 1.Laboratory of Clinical Pharmacology, Cancer Research and Treatment Center University of New Mexico, School of MedicineAlbuquerqueUSA
  2. 2.Department of MedicineUniversity of New Mexico, School of MedicineAlbuquerqueUSA
  3. 3.Department of PharmacologyUniversity of New Mexico, School of MedicineAlbuquerqueUSA
  4. 4.College of PharmacyAlbuquerqueUSA

Personalised recommendations